Ignite Creation Date:
2024-05-05 @ 11:07 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006473
Status:
COMPLETED
Last Update Posted:
2013-01-23
First Post:
2000-11-06
Brief Title:
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkins Lymphoma
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkins Lymphoma
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkins lymphoma Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
OBJECTIVES
I Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkins lymphoma
II Determine the treatment-related toxicity of this drug in these patients
OUTLINE This is a multicenter study Patients are stratified according to histologic subtype indolent vs aggressive
Patients receive oxaliplatin IV over 2 hours on day 1 Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A maximum of 72 patients will be accrued for this study within 2-3 years
I Determine the response rate to oxaliplatin in patients with relapsed or refractory non-Hodgkins lymphoma
II Determine the treatment-related toxicity of this drug in these patients
OUTLINE This is a multicenter study Patients are stratified according to histologic subtype indolent vs aggressive
Patients receive oxaliplatin IV over 2 hours on day 1 Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity
PROJECTED ACCRUAL A maximum of 72 patients will be accrued for this study within 2-3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000068297 | REGISTRY | PDQ Physician Data Query | None |
| ID99-406 | None | None | None |